Pulmatrix, Inc. entered into a merger agreement with Eos SENOLYTIX, Inc. on March 26, 2026, under which Eos will become a wholly owned subsidiary, with Eos stockholders expected to own approximately 94% of the combined company. The transaction includes concurrent private financings totaling up to $19 million and is subject to customary closing conditions, including stockholder approvals.
Key takeaways
Pulmatrix entered into a merger agreement with Eos SENOLYTIX on March 26, 2026, where Eos will become a wholly owned subsidiary.
Pre-Merger Eos stockholders are expected to own approximately 94% of the combined company, with Pulmatrix stockholders owning approximately 6%.
Concurrent private financings include a $1 million Pulmatrix financing via Series B Preferred Stock and an Eos financing for up to $18 million.
The merger is subject to closing conditions including Pulmatrix and Eos stockholder approvals, Nasdaq listing approval, and SEC registration statement effectiveness.
At the effective time, the Pulmatrix board is expected to consist of six members, with five designated by Eos and one by Pulmatrix.
Senotherapeutix, Inc., the sole holder of Eos capital stock, entered into support and lock-up agreements related to the merger.